Abstract
The standard treatment regimen for locally recurrent lesions is total thyroidectomy, or complete removal of the recurrent thyroid lesion within the thyroid bed. However, reoperation increases the risk of complications and patients have to undergo general anesthesia. Percutaneous ethanol injection therapy represents a far less invasive procedure without general anesthesia and with lower risk of complications. Thirty-four patients who received PEIT at Yonsei University Medical Center between October 2002 and August 2009 for recurrent cervical nodal metastases of differentiated papillary thyroid cancer were included in this retrospective study. During a minimum follow-up of 60 months, treatment outcomes were determined by measuring the lesion size prior to the first injection and 3 months after the last injection. A total of 46 recurrent lesions were detected in 34 patients. Five patients underwent surgery and PEIT was administered to the remaining 19 and 22 lesions in the central compartment and lateral neck lymph nodes, respectively. Size increases were observed in seven (17.1%) lesions, whereas no changes in size and decreases were detected in 10 (24.4%) and 24 (58.5%) lesions. Patients with increased lymph nodes were significantly older (65.3 ± 14.4 vs. 48.2 ± 16.3 years; p = 0.02) and had smaller sizes (9.3 ± 1.0 vs. 12.3 ± 6.4 mm; p = 0.012). Although reoperation remains the first-line treatment for recurrent thyroid cancer, PEIT may be considered as a treatment option in selected patients with lesions larger than 1 cm who are ineligible for surgery or have refused reoperation.
Similar content being viewed by others
References
Greenlee RT, Hill-Harmon MB, Murray T, Thun M (2001) Cancer statistics, 2001. CA Cancer J Clin 51(1):15–36
Hundahl SA, Fleming ID, Fremgen AM, Menck HR (1998) A National Cancer Data Base report on 53,856 cases of thyroid carcinoma treated in the U.S., 1985–1995 [see comments]. Cancer 83(12):2638–2648
Kim WB (2015) A closer look at papillary thyroid carcinoma. Endocrinol Metab 30(1):1–6. doi:10.3803/EnM.2015.30.1.1
Dralle H, Machens A (2013) Surgical management of the lateral neck compartment for metastatic thyroid cancer. Curr Opin Oncol 25(1):20–26. doi:10.1097/CCO.0b013e328359ff1f
Shin JE, Baek JH, Lee JH (2013) Radiofrequency and ethanol ablation for the treatment of recurrent thyroid cancers: current status and challenges. Curr Opin Oncol 25(1):14–19. doi:10.1097/CCO.0b013e32835a583d
Sohn YM, Hong SW, Kim EK, Kim MJ, Moon HJ, Kim SJ, Son EJ, Kwak JY (2009) Complete eradication of metastatic lymph node after percutaneous ethanol injection therapy: pathologic correlation. Thyroid 19(3):317–319. doi:10.1089/thy.2008.0370
Heilo A, Sigstad E, Fagerlid KH, Haskjold OI, Groholt KK, Berner A, Bjoro T, Jorgensen LH (2011) Efficacy of ultrasound-guided percutaneous ethanol injection treatment in patients with a limited number of metastatic cervical lymph nodes from papillary thyroid carcinoma. J Clin Endocrinol Metab 96(9):2750–2755. doi:10.1210/jc.2010-2952
Lim CY, Yun JS, Lee J, Nam KH, Chung WY, Park CS (2007) Percutaneous ethanol injection therapy for locally recurrent papillary thyroid carcinoma. Thyroid 17(4):347–350. doi:10.1089/thy.2006.0251
Fontenot TE, Deniwar A, Bhatia P, Al-Qurayshi Z, Randolph GW, Kandil E (2015) Percutaneous ethanol injection vs reoperation for locally recurrent papillary thyroid cancer: a systematic review and pooled analysis. JAMA Otolaryngol Head Neck Surg 141(6):512–518. doi:10.1001/jamaoto.2015.0596
Vannucchi G, Covelli D, Perrino M, De Leo S, Fugazzola L (2014) Ultrasound-guided percutaneous ethanol injection in papillary thyroid cancer metastatic lymph-nodes. Endocrine 47(2):648–651. doi:10.1007/s12020-014-0215-0
Lewis BD, Hay ID, Charboneau JW, McIver B, Reading CC, Goellner JR (2002) Percutaneous ethanol injection for treatment of cervical lymph node metastases in patients with papillary thyroid carcinoma. AJR Am J Roentgenol 178(3):699–704. doi:10.2214/ajr.178.3.1780699
Hay ID, Lee RA, Davidge-Pitts C, Reading CC, Charboneau JW (2013) Long-term outcome of ultrasound-guided percutaneous ethanol ablation of selected “recurrent” neck nodal metastases in 25 patients with TNM stages III or IVA papillary thyroid carcinoma previously treated by surgery and 131I therapy. Surgery 154(6):1448–1454. doi:10.1016/j.surg.2013.07.007 (discussion 1454–1445)
Leenhardt L, Erdogan MF, Hegedus L, Mandel SJ, Paschke R, Rago T, Russ G (2013) 2013 European thyroid association guidelines for cervical ultrasound scan and ultrasound-guided techniques in the postoperative management of patients with thyroid cancer. Eur Thyroid J 2(3):147–159. doi:10.1159/000354537
Gharib H, Papini E, Garber JR, Duick DS, Harrell RM, Hegedus L, Paschke R, Valcavi R, Vitti P, Nodules AAATFoT (2016) American Association of Clinical Endocrinologists, American College of Endocrinology, and Associazione Medici Endocrinologi medical guidelines for clinical practice for the diagnosis and management of thyroid nodules—2016 update. Endocr Pract 22(5):622–639. doi:10.4158/EP161208.GL
Kim BM, Kim MJ, Kim EK, Park SI, Park CS, Chung WY (2008) Controlling recurrent papillary thyroid carcinoma in the neck by ultrasonography-guided percutaneous ethanol injection. Eur Radiol 18(4):835–842. doi:10.1007/s00330-007-0809-5
Akasu H, Shimizu K, Kitagawa W, Naito Z, Kawanami O, Tanaka S (2002) Histological study of papillary thyroid carcinoma treated with percutaneous ethanol injection therapy. Pathol Int 52(5–6):406–409
Mauz PS, Maassen MM, Braun B, Brosch S (2004) How safe is percutaneous ethanol injection for treatment of thyroid nodule? Report of a case of severe toxic necrosis of the larynx and adjacent skin. Acta Otolaryngol 124(10):1226–1230
Mauz PS, Stiegler M, Holderried M, Brosch S (2005) Complications of ultrasound guided percutaneous ethanol injection therapy of the thyroid and parathyroid glands. Ultraschall Med 26(2):142–145. doi:10.1055/s-2005-857867
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Funding
The authors received no financial support for the research, authorship, and/or publication of this article.
Ethical standards
This study was approved by the ethics committee (IRB 3-2016-0126).
Conflict of interest
The authors declare that they have no conflict of interest.
Ethical approval
For this type of study, formal consent is not required.
Informed consent
Informed consent was obtained from all individual participants included in the study.
Rights and permissions
About this article
Cite this article
Kim, S.Y., Kim, SM., Chang, H. et al. Long-term outcomes of ethanol injection therapy for locally recurrent papillary thyroid cancer. Eur Arch Otorhinolaryngol 274, 3497–3501 (2017). https://doi.org/10.1007/s00405-017-4660-2
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00405-017-4660-2